CD4 Antibody, anti-human, REAfinity™
Synonyms: T4, Leu-3, CD4mut
RECOMBINANT EXTENDED VALIDATION
Bioz Star97/100 Bioz rating
304 Citations93 Images
Clone:
REA623 | SK3
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, 3D-IF, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD4 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 615
PE-Vio 670
PE-Vio 770
PerCP-Vio 700
Vio B515
Vio Bright B515
Vio Bright FITC
Vio Bright R667
Vio Bright R720
Vio Bright V423
Vio Bright V600
Vio Bright V646
Vio Bright V710
Vio Bright V787
Vio R667
VioBlue
VioGreen
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-113-222, 130-113-784
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with CD4 antibodies or with the corresponding REA Control (S) antibodies (left images) as well as with CD3 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-113-784, 130-113-222
Testing grade:
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-113-784, 130-113-222
Testing grade:
3D-Immunofluorescence applications
Vio R667
Tissue clearing:
MACS® Clearing Kit
Fixation:
PFA
Species tested:
human
Tissue used:
colorectal cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
Vio R667
Used products:
130-131-639
Description:
3D-immunofluorescence analysis of a human colorectal carcinoma fixed with 4% PFA and subjected to whole-mount immunostaining with CD4 Antibody, anti-human, Vio® R667 (red). The sample was processed and optically cleared using the MACS® Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. Single layer zoom-in on sample (A) and overview of the whole sample (B, autofluorescence in grey). Maximum intensity projection of 100µm sample (C, autofluorescence in grey) and 3D rendering (autofluorescence in grey) (D). Scale bars: 300µm (A, C); 500µm (B)

A

Application imageView details view details

B

Application imageView details view details

C

Application imageView details view details

D

Application imageView details view details
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-122-283
Reported:
Extended validation for CD4 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA623
RPA-T4
low
SK3
high
OKT4
low
VIT4
low
M-T466
high
M-T321
high

Cells were incubated with an excess of purified unconjugated CD4 (REA623) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD4. Human peripheral blood mononuclear cells (PBMCs) were stained with CD4 antibodies and with a suitable counterstaining. As a control, CD4 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Monocytes were excluded from the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD4 (REA623). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD4 Antibody, anti-human, REAfinity™
Overview

Clone REA623 recognizes the human CD4 antigen, a 55 kDa single-pass type I membrane protein, also known as T4/Leu-3. CD4 is highly expressed on T helper cells and at a lower level on monocytes and dendritic cells. It is involved in the recognition of MHC class II/peptide complexes by the TCR heterodimers and is the receptor for the human immunodeficiency virus (HIV).

Additional information: Clone REA623 displays negligible binding to Fc receptors.

Alternative names

T4, Leu-3, CD4mut

Detailed product information

Technical specifications

Clone
REA623
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD4
Molecular mass of antigen [kDa]
48
Distribution of antigen
monocytes, T cells, T helper cells, thymocytes, neutrophils
Entrez Gene ID
RRID
AB_2726310, AB_2726308, AB_2726315, AB_2726036, AB_2734020, AB_2726311, AB_2726040, AB_2734019, AB_2726033, AB_2905065, AB_2905064, AB_2801864, AB_2726037, AB_2726039, AB_2726313, AB_2726980, AB_2905062, AB_2726922, AB_2726316, AB_2905063, AB_2726314, AB_2751241, AB_2726035, AB_2726309, AB_2726921, AB_2726041, AB_2726034, AB_2726774, AB_2726691, AB_2726690, AB_2751238, AB_2726312, AB_2726703, AB_2726038, AB_2726775, AB_2726979

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD4 Antibody, anti-human, REAfinity™
Documents and Protocols
App notes/customer reports
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support